Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
NCT ID: NCT03937947
Last Updated: 2024-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2019-09-28
2023-09-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is an observational pilot that aims to define the incidence of proximal DVT in patients with moderate to severe TBI. It seeks prospectively to determine if there is an association between DVT and outcome. It also seeks to explore possible associations between the occurrence of DVT and the incidence of lung injury and/or ventilator associated pneumonia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin
NCT03611894
The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke
NCT05636748
The Utility of Thromboelastography in Traumatic Brain Injury
NCT04524637
Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations
NCT02013635
Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients
NCT07235423
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Paradoxically however, despite these concerns over the use of PT in this population of patients, evidence of harm associated with the confirmed presence of proximal DVT is not yet convincing. This has additional significance as without clear evidence of harm associated with DVT complicating TBI, trials to address the questions of safety and efficacy of earlier use of PT are difficult to design and unlikely to attract the necessary funding.
From a search of a trauma registry of patients at risk of DVT who underwent venous screening, in TBI patients the occurrence of DVT was associated with increased ventilator days (Mean (SD), 18.0 (14.9) vs. 9.3 (7.9) days for DVT vs. no DVT, p=0.014) and ICU length of stay (23.0 (14.5) vs. 13.1 (9.8) days for DVT vs. no DVT, p=0.006). Similar results were seen in a post hoc analysis of the EPO TBI trial. This was a randomised controlled trial (RCT) of the effect of erythropoietin (EPO) verses placebo on outcome following TBI. Repeated lower limb screening for the presence of DVT was conducted as part of the protocol. Both ventilator days (Median (IQR) 11 (6-17) vs. 8 (4-14) days for DVT vs. no DVT, p\<0.001) and ICU length of stay (17 (11-22) vs. 12 (6-19) days DVT vs. no DVT, p\<0.001). Good neurological outcome at 6 months was significantly less frequent in those that developed DVT (45.4 vs. 57.9% DVT vs. no DVT, p=0.01). Whilst these findings are clinically important they are the result of retrospective and post hoc analysis. They therefore require to be prospectively validated if they are to be accepted.
One possible explanation for an increase in ventilator dependency and ICU length of stay could be the occurrence of undiagnosed pulmonary emboli causing acute lung injury (ALI). The occurrence of ventilation perfusion mismatching, deterioration in arterial partial pressure: fraction inspired oxygen ratio (PaO2:FiO2) and radiological changes on chest x-ray, being interpreted as evidence of pulmonary infection. This is supported by local audit data from June to October 2017 which found that 37% of brain injured patients had a clinical diagnosis of ventilator associated pneumonia (VAP) and were treated with antibiotics but lacked subsequent microbiological confirmation. It is also possible that small pulmonary emboli might predispose to pulmonary infection, explaining why the incidence of ventilator associated pneumonia (VAP) remains high in this population (40%, in the same local audit) despite the adoption of measures which have lowered VAP rates in other critically ill patient groups.
Lung Brain "cross-talk" could link evidence of ALI to a negative impact on neurological outcome in these patients. A disproportionate increase in mortality in patients with TBI and ALI has been reported. This was greatly in excess of deaths attributable to pulmonary dysfunction. Similarly, in animal models, ALI was found to be associated with cognitive impairment, and biomarker/histological evidence of neuronal injury.
This is a prospective, potentially multi centre, observational pilot study that aims to determine the incidence of DVT after TBI. Patients admitted to an ICU within 72 hours of suffering a TBI will be eligible for inclusion. The study will run for 2 years with a 16 month recruitment period. Based on current activity in Edinburgh the investigators estimate that 50 to 60 patients will be eligible for recruitment over the course of the study. In order to ensure satisfactory recruitment, the investigators will also approach centres that have expressed an interest.
Once consent is obtained for the patient to be enrolled in the study, a compression ultrasound scan (USS) of both legs will be carried out as soon as possible so that the first USS is completed within 72 hours of injury. USS will be repeated on alternate days up to Day 10 from injury. Daily data collection will include information on the use of mechanical and pharmacological thromboprophylaxis, ventilator dynamics including FiO2 and PaO2, chest X ray reports, clinical and microbiological diagnosis of ventilator associated pneumonia, ventilator days and ICU and hospital length of stay. The Modified Oxford Handicap Scale will be completed for all patients on day 28, hospital discharge or death whichever is sooner Patients will then be followed up at 6 months by the study team, at which time an extended Glasgow Outcome Scale Questionnaire will be completed.
An amendment to the protocol is also being prepared to include assessment of blood coagulation by standard laboratory testing and viscoelastic methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Admission to critical care
3. moderate/severe, non-penetrating traumatic brain injury
4. Abnormal brain CT Scan
5. Post resuscitation Glasgow coma score (GCS) ≤12, or GCS motor component ≤5
6. Able to complete consent and first USS within 72 hours of injury
Exclusion Criteria
2. Unlikely to survive for the next 24 hours in the opinion of the ICU Consultant or Consultant Neurosurgeon treating the patient
3. Contra indication to normal prophylactic measures, including heparin, were indicated
4. Known blood clotting disorder or thrombophilia
5. Significant pelvic or lower limb trauma
6. Malignancy
7. Pregnancy or recently post-partum
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NHS Lothian
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan Rhodes
Consultant in Intensive Care and Anaesthesia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensive Care Unit, Western General Hospital
Edinburgh, Midlothian, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WKR0-2018-0020
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
WKR0-2018-0020
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
AC18105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.